These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. Fodale V; Boggio R; Daldin M; Cariulo C; Spiezia MC; Byrne LM; Leavitt BR; Wild EJ; Macdonald D; Weiss A; Bresciani A J Huntingtons Dis; 2017; 6(4):349-361. PubMed ID: 29125493 [TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment. Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395 [TBL] [Abstract][Full Text] [Related]
7. Is there a role of Tau in Huntington's disease? Zerr I; Bähr M J Neurochem; 2016 Oct; 139(1):9-10. PubMed ID: 27651306 [TBL] [Abstract][Full Text] [Related]
8. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. Ou ZA; Byrne LM; Rodrigues FB; Tortelli R; Johnson EB; Foiani MS; Arridge M; De Vita E; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ Sci Rep; 2021 Feb; 11(1):3481. PubMed ID: 33568689 [TBL] [Abstract][Full Text] [Related]
9. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease. van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706 [TBL] [Abstract][Full Text] [Related]
10. A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward. Silajdžić E; Björkqvist M J Huntingtons Dis; 2018; 7(2):109-135. PubMed ID: 29614689 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. Byrne LM; Rodrigues FB; Johnson EB; De Vita E; Blennow K; Scahill R; Zetterberg H; Heslegrave A; Wild EJ Sci Rep; 2018 Mar; 8(1):4260. PubMed ID: 29523800 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease. Barschke P; Abu-Rumeileh S; Al Shweiki MHDR; Barba L; Paolini Paoletti F; Oeckl P; Steinacker P; Halbgebauer S; Gaetani L; Lewerenz J; Ludolph AC; Landwehrmeyer GB; Parnetti L; Otto M J Neurol; 2022 Sep; 269(9):5136-5143. PubMed ID: 35737109 [TBL] [Abstract][Full Text] [Related]
13. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis. Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J Elife; 2021 Apr; 10():. PubMed ID: 33871358 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease. Korpela S; Sundblom J; Zetterberg H; Constantinescu R; Svenningsson P; Paucar M; Niemelä V J Neurol Sci; 2024 Apr; 459():122979. PubMed ID: 38569376 [TBL] [Abstract][Full Text] [Related]
18. Fluid and imaging biomarkers for Huntington's disease. Zeun P; Scahill RI; Tabrizi SJ; Wild EJ Mol Cell Neurosci; 2019 Jun; 97():67-80. PubMed ID: 30807825 [TBL] [Abstract][Full Text] [Related]
19. Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. Huang YC; Wu YR; Tseng MY; Chen YC; Hsieh SY; Chen CM PLoS One; 2011 Jan; 6(1):e15809. PubMed ID: 21297956 [TBL] [Abstract][Full Text] [Related]